Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Indicating radiotherapy after breast-conserving therapy & mastectomy

Orit Kaidar-Person • 13 Mar 2025
BCC 2025
Breast Cancer

Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel, provides an overview of advancements in radiation therapy following breast-conserving surgery, including strategies to reduce side effects and treatment duration. There has been a shift away from a one-size-fits-all approach, offering more personalized options for patients. Prof. Kaidar-Person also discusses considerations for radiation therapy in immediate breast reconstruction, focusing on minimizing complications and improving outcomes. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Orit Kaidar-Person

The role of regional node irradiation for low-burden breast cancer
0:53
The role of regional node irradiation for low-burden breast cancer
Orit Kaidar-Person • 13 Mar 2025
Do all low-burden breast cancer cases need regional node irradiation?
0:50
Do all low-burden breast cancer cases need regional node irradiation?
Orit Kaidar-Person • 13 Mar 2025
Unanswered questions in early breast cancer care at St Gallen 2025
0:40
Unanswered questions in early breast cancer care at St Gallen 2025
Orit Kaidar-Person • 13 Mar 2025
Tailoring radiation therapy for breast cancer based on recurrence risk
1:05
Tailoring radiation therapy for breast cancer based on recurrence risk
Orit Kaidar-Person • 16 May 2024

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals